Grants and Contributions:
Title:
Development and validation of T Cell Immunoassay for immuno-oncology
Agreement Number:
983842
Agreement Value:
$35,200.00
Agreement Date:
Jan 3, 2022 - Aug 31, 2022
Description:
This project will involve the development and validation of an assay to detect tumor associated antigen (TAA) and tumor neoantigen (TN)-specific cancer fighting T cells in a small sample of peripheral blood to as a diagnostic assay to 1) identify candidates for immune checkpoint inhibitor (ICI) treatment and 2) assess the ability to mount an anti-tumor immune response after immunotherapy or chemotherapy.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V5Z 3Y1
Reference Number:
172-2021-2022-Q4-983842
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
705017879
Recipient Type:
For-profit organization
Recipient's Legal Name:
Immunity Diagnostics Inc
Federal Riding Name:
Vancouver Granville
Federal Riding Number:
59036
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
6215